CDK4 and cancer: Zhang et al. reported cyclin D1-CDK4/6 signaling is an important upstream regulator of PD-L1 degradation, and upregulation of PD-L1 by CDK4/6 inhibition sensitized cancer cells to checkpoint inhibitor therapy 15.